APPROACH TO PLEURAL EFFUSIONS

METU Talk

DIAGNOSTIC EVALUATION

- Careful Hx and PE
 - Eg, patient with obvious cause may not need further study (CHF with bilateral effusions, CA)
- Thoracentesis
 - Likely indicated in most patients
 - > 1 cm layering on lateral decubitus Xray,
 OK
 - < 1 cm: observe or u/s guidance

PLEURAL FLUID STUDIES

- Light's Criteria
 - Pleural LDH/Serum LDH > 0.6* -OR-
 - Pleural protein/Serum protein > 0.5 -OR-
 - Pleural LDH > 2/3 upper limit of normal (serum)
 - Usually > 200 IU
- Presence of ANY one: exudate
- Absence of ALL: transudate
- Sensitivity 99%, Specificity 98%
- *LDH and "six" each have 3 letters

PLEURAL FLUID STUDIES* Other Initial Diagnostic Studies

Pleural Fluid Studies Cutoff Point

Pleural Fluid Protein > 2.9 g/dL

Pleural Fluid LDH >0.45 upper limits

of normal

Pleural Fluid Chol >45 mg/dL

Pleural chol/Serum Chol > 0.3

Pleural albumin/Serum albumin 1.2 g/dL

Pleural bilirubin/Serum bilirubin > 0.6

*Heffner JE. Clinics in Chest Medicine. 1998;19:277-93.

PLEURAL FLUID STUDIES

- Most cost effective approach:
 - Order LDH, Protein labs
 - Hold fluid
 - Further studies ONLY if tests confirm exudate

TRANSUDATIVE EFFUSIONS Clinical Diagnosis is Key

- CHF
 - Diuretic therapy can alter transudates to exudates
- Cirrhosis
- Nephrotic Syndrome
- Constrictive Pericarditis
- Atelectasis
- Peritoneal Dialysis
- Urinothorax (low pH, 1 pl/serum creatinine)
- Pulmonary Embolism (20% of effusions trans)
- Malnutrition

- Initial diagnostic tests
 - Cell count with differential
 - Cytology
 - Gm stain, culture, AFB smear/culture
 - Glucose

- RBC > 100,000/ mm
 - Malignancy, trauma, PE
 - > 10,000: common, not helpful
- Mesothelial cells
 - Low (< 5%) may be due to TB, empyema, pleurodesis
 - > 5% helps eliminate these as etiology
- Cytology
 - If initial fluid assuredly benign: < 3% chance of CA
 - If suspicious: repeat up to 3 times may be needed

- WBC
 - PMNs: para-pneumonic, PE, rheumatoid
 - Does NOT R/O TB or CA
 - Lymphocyte predominant (>50%)
 - TB or CA
 - Sarcoid, lymphoma, rheumatoid arthritis
 - Eosinophilic (> 10% eos)
 - CA, trauma, pneumonia, parasites, asbestos, PTX
 - Rare with TB
 - Up to 1/3 idiopathic

- Lymphocytic (> 50%)
 - CA (30-35%)
 - TB (15-20%)
 - Sarcoidosis
- PMNs
 - Empyema
 - Parapneumonic
 - Rheumatoid
 - Pulmonary infarction
- PMN or Lymphocytic
 - PE
 - Conn tissue disease
 - Post-cardiac injury

- Eosinophilic (> 10%)
 - Trauma
 - PTX
 - CA
 - Asbestos, parasites
 - Pneumonia
- RBC > 100,000/mm
 - CA
 - Trauma
 - Pulmonary infarction

EXUDATIVE EFFUSIONS Other Tests

Suspected TB

- Adenosine deaminase (> 50 IU/L)
- B₂ microglobulin
- Lysozyme III (> 20mcg/mL)
- PCR (Sens 100%, Spec 95%)
- AFB (smear 10-20%; cx 25-50%)
- PPD
- Suspected Rheumatoid
 - Pleural RF
 - Low glucose

Suspected SLE

- SerumComplement
- Pleural ANA
- LE cells prep?
- Suspected Pneumonia
 - pH
- Suspected Pancreatitis
 - Pleural Amylase

BEYOND THORACENTESIS

- Pleural Biopsy
 - Most helpful in evaluating for TB
 - Limited utility for CA (40-50% positive)
 - Repeat cytology x 3
 - Sarcoid, fungal: might be helpful
- Thoracoscopy
 - Most helpful in evaluating for malignancy

UNDIAGNOSED PLEURAL EFFUSIONS

- 15-20% of effusions
- Careful review of history, PE, meds, risk factors
- Consider occult abdominal process
- Consider PE

UNDIAGNOSED PLEURAL EFFUSIONS Cont'd

- Risk factors for TB or malignant effusion
 - Weight loss > 4.5 kg (10 pounds)
 - Fever > 38 C
 - Positive PPD
 - Large effusion (> 1/2 hemithorax)
 - < 95% lymphs in pleural fluid
- If ANY factor present, evaluate for TB, CA

UNDIAGNOSED PLEURAL EFFUSIONS Cont'd

PPD

- If (+) and lymphocytic effusion, initiate TB treatment
- If (-), repeat in 6-8 wks
 - However, if effusion < 5% mesothelial cells, consider TB treatment
- If (-), not anergic, > 5% mesothelial cells, wait for repeat PPD in 6-8 wks
- If repeat PPD (-), not anergic and cultures negative, observe

REFERENCES

- Ansari T, Idell S. Diseases of the pleura; management of undiagnosed persistent pleural effusions. Clin Chest Med. 1998;19:407-17.
- Heffner JE. Evaluating diagnostic tests in the pleural space; differentiating transudates from exudates as a model. Clin Chest Med. 1998;19:277-93.